Sugammadex Injection [Bridion] + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Posterior Cervical Decompression and Fusion
Conditions
Posterior Cervical Decompression and Fusion
Trial Timeline
Feb 5, 2018 → Apr 30, 2020
NCT ID
NCT03087513About Sugammadex Injection [Bridion] + Placebo
Sugammadex Injection [Bridion] + Placebo is a approved stage product being developed by Merck for Posterior Cervical Decompression and Fusion. The current trial status is completed. This product is registered under clinical trial identifier NCT03087513. Target conditions include Posterior Cervical Decompression and Fusion.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03087513 | Approved | Completed |
Competing Products
10 competing products in Posterior Cervical Decompression and Fusion
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| Adalimumab | AbbVie | Approved | 85 |
| Esomeprazole + Placebo | AstraZeneca | Approved | 85 |
| Azithromycin ophthalmic solution, 1% | Merck | Phase 2 | 52 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| REGN7041 | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 49 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Sham Injection + FAI Insert | EyePoint Pharmaceuticals | Phase 3 | 72 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 44 |